Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Avantsar Sdn Bhd currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is being handled by 1 distinct examiner and is located within 1 distinct art unit. This indicates a narrow and focused prosecution footprint at the present time. The examiner assigned to this case is SCHMIDT, IZABELA MARIA, who holds 1 pending office action. Because there are no other active matters, the outcome of this 1 pending office action will define the company's current progress in the Biotechnology & Pharmaceuticals field.
The concentration of 1 pending office action under 1 distinct examiner in 1 distinct art unit simplifies the management of the portfolio. Practitioners can dedicate their efforts to understanding the specific requirements of SCHMIDT, IZABELA MARIA within the Biotechnology & Pharmaceuticals sector. The stability of having 1 distinct art unit involved ensures a consistent administrative framework for the application. Practitioners should focus on the specific precedents and preferences of this 1 distinct examiner to move the application toward allowance, as their individual perspective is the primary factor in the current prosecution cycle. This targeted approach is necessary for securing the company's biotechnology intellectual property.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHMIDT, IZABELA MARIA | 1 | 65.7% | +42.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18578252 | A SELF-EMULSIFYING DRUG DELIVERY FORMULATION WITH IMPROVED ORAL BIOAVAILABILITY OF LIPOPHILIC COMPOUND | SCHMIDT, IZABELA MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18578252 | A SELF-EMULSIFYING DRUG DELIVERY FORMULATION WITH IMPROVED ORAL BIOAVAILABILITY OF LIPOPHILIC COMPOUND | SCHMIDT, IZABELA MARIA | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18578252 | A SELF-EMULSIFYING DRUG DELIVERY FORMULATION WITH IMPROVED ORAL BIOAVAILABILITY OF LIPOPHILIC COMPOUND | SCHMIDT, IZABELA MARIA | 1621 | §102§103 | Final Rejection | — | Pending | Jan 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAvantsar Sdn Bhd has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Izabela Maria Schmidt has the most, with 1 of Avantsar Sdn Bhd's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
